- Status:
- In progress
- Decision:
- Prioritised
- Process:
- TA
- Referral date:
- 01 March 2015
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- 3 November 2015
- 1st appraisal committee meeting::
- 16 February 2016
Project Team
- Project lead
- Liv Gualda
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Liverpool Reviews and Implementation Group (LRIG)
Stakeholders
- Companies sponsors
- Amgen
- Others
- Department of Health
- NHS England
- Welsh Government
- Professional groups
- Association of Cancer Physicians
- British Association of Skin Cancer Specialist Nurses
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health England
- Public Health Wales
- Comparator companies
- Bristol-Myers Squibb Pharmaceutical (ipilimumab)
- Roche Products (vemurafenib)
- Evidence review group
- Liverpool Reviews and Implementation Group (LRIG)
- General commentators
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Relevant research groups
- National Institute for Health Research Technology Assessment Programme (NETSCC)?
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 September 2016 | Expected publication |
| 09 August 2016 - 23 August 2016 | Final appraisal determination |
| 16 March 2016 - 13 April 2016 | Draft guidance: 508 |
For further information on our processes and methods, please see our CHTE processes and methods manual